Clovis Oncology, Inc. (CLVS)

MARION, NC / ACCESS Newswire / September 23, 2025 / Greene Concepts Inc. (OTCID:INKW), a publicly traded beverage and bottling company and proud owner of the Be Water™ artesian spring water brand, announces its sponsorship of the 5th Annual Children's Business Fair, taking place September 27-28, 2025, in Clovis, California. The company has donated multiple cases of Be Water™ and partnered with the Central Valley Young Entrepreneurs (CVYE) organization to support the event while showcasing its brand.

Geneva, Switzerland , Sept. 03, 2025 (GLOBE NEWSWIRE) -- Olivier Clovis Scaling Business , a Swiss-based coaching and digital strategy company, announced today the launch of a specialized sales funnel coaching program designed to help entrepreneurs scale their online businesses. The program, developed by founder and sales funnel expert Olivier Clovis, introduces a proven customer journey model that guides low-ticket buyers toward high-ticket offers—helping business owners recoup ad spend early, increase client conversion rates, and grow sustainably in a competitive digital landscape.

The performance of penny stocks continues to be mixed relative to more widely-followed stocks, but if you've looking for the best penny stocks to buy now, this works to your advantage. As has been the case in recent months, there are plenty of names in “penny stock territory” ($5 per share or less) trading at low valuations, with catalysts in play that over the long-term stand to help bridge the gap between trading price and underlying value.

Forget undervalued stocks, play top-ranked stocks like Clovis Oncology (CLVS), NiSource (NI), DocuSign (DOCU), Root (ROOT) and Endava (DAVA).

Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

Clovis Oncology (NASDAQ: CLVS ) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection. The first thing that investors need to know about is Clovis Oncology's plan for this bankruptcy.

Clovis Oncology Inc. stock CLVS, -9.94% fell 10% in premarket trade Monday, after the biotech filed for Chapter 11 bankruptcy and said it would sell assets. The company has a commitment for up to $75 million in debtor-in-possession financing to provide the liquidity needed to restructure in bankruptcy and pay its vendors and customers.

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the “Debtors”) have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware (“Bankruptcy Court”) and will seek to sell their assets through a court supervised sales process. The Debtors have filed various “first day” motions with the Bankruptcy Court requesting customary relief that will enable them to transition into Chapter 11 without material disruption to their ordinary course operations, including seeking authority to obtain debtor-in-possession (“DIP”) financing and pay employee wages and benefits. DIP Financing In order to provide necessary funding during the Chapter 11 proceeding, Clovis has received a commitment of up to $75 million in a multi-draw DIP financing facility. Upon approval by the Bankruptcy Court, the DIP financing is expected to provide Clovis with the necessary liquidity to operate in the normal course and meet obligations to its employees, vendors and customers throughout the Chapter 11 proceeding while executing on the sales process. Sales Process Prior to the Chapter 11 filing, and subject to Bankruptcy Court approval, the Company entered into a “stalking horse” purchase and assignment agreement with Novartis Innovative Therapies AG (“Novartis”) to acquire substantially all of the rights of the Company to its pipeline clinical candidate, FAP-2286, as a therapeutic agent for an upfront payment of $50 million and up to an additional $333.75 million upon the successful achievement of specified development and regulatory milestones and $297 million in later sales milestones. The transaction is part of a sale process under Section 363 of the Bankruptcy Code that will be subject to compliance with agreed upon and Bankruptcy Court-approved bidding procedures allowing for the submission of higher or otherwise better offers, and other agreed-upon conditions. In addition, the transaction is subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. In accordance with the sale process under Section 363 of the Bankruptcy Code, notice of the proposed sale to Novartis will be given to third parties and competing bids will be solicited. The Company will manage the bidding process and evaluate any bids received, in consultation with its advisors and as overseen by the Bankruptcy Court. Clovis is also actively engaged in discussions with a number of interested parties with respect to a potential sale of one or more of its other assets. Any of those sales would be subject to review and approval by the Bankruptcy Court and compliance with Bankruptcy Court-approved bidding procedures. Clovis is represented by Willkie Farr & Gallagher LLP as counsel, AlixPartners LLP as restructuring advisor and Perella Weinberg Partners L.P. as restructuring investment banker. Additional information about the Chapter 11 case, including access to Bankruptcy Court documents, is available online at https://cases.ra.kroll.com/Clovis. Forward-Looking Statements This press release includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These forward-looking statements reflect the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. Clovis’ forward-looking statements in this press release include, but are not limited to, statements about Clovis’ plans to sell its assets pursuant to Chapter 11 of the U.S. Bankruptcy Code and the timing of such sales and ability to satisfy closing conditions; Clovis’ intention to continue operations during the Chapter 11 case; Clovis’ belief that the sale process will be in the best interest of Clovis and its stakeholders; and other statements regarding Clovis’ strategy and future operations, performance and prospects, among others. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Clovis will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Clovis’ control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks associated with the potential adverse impact of the Chapter 11 filings on Clovis’ liquidity and results of operations; changes in Clovis’ ability to meet its financial obligations during the Chapter 11 process and to maintain contracts that are critical to its operations; the outcome and timing of the Chapter 11 process and any potential asset sale; the effect of the Chapter 11 filings and any potential asset sale on Clovis’ relationships with vendors, regulatory authorities, employees and other third parties; possible proceedings that may be brought by third parties in connection with the Chapter 11 process or the potential asset sale; uncertainty regarding obtaining Bankruptcy Court of a sale of Clovis’ assets or other conditions to the potential asset sale; and the timing or amount of any distributions, if any, to Clovis’ stakeholders.

BOULDER, Colo.--( BUSINESS WIRE )--Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the “Debtors”) have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware (“Bankruptcy Court”) and will seek to sell their assets through a court supervised sales process.

Investors in Clovis Oncology (NASDAQ: CLVS ) stock will want to prepare for a bankruptcy filing following a warning from the pharmaceutical company. According to a filing with the U.S. Securities and Exchange Commission (SEC), the company is expecting to file for Chapter 11 bankruptcy protection.

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

Clovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Once again, I drew the short (no pun intended) end of the stick and must discuss stocks to sell right now. Understandably a sensitive topic and one that arouses myriad emotions, I'm just going to stick with the hard numbers.

Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?

There's nothing like a good old-fashioned bankruptcy warning to make a stock pop on a given day. Today, the latest speculative frenzy appears to be underway with Clovis Oncology (NASDAQ: CLVS ).